Mario Negri Institute for Pharmacological Research: all 159 studies
Page 2 of 2. Open to participants first (36), then studies with results posted, then the rest; newest registration first within each.
- Remission Clinic in Proteinuric Chronic NephropathiesStatus unknownNCT02721342
- Renal NCE-MRI in Healthy VolunteersCompletedNCT02618460Not applicable
- NEPHSTROM for Diabetic Kidney DiseaseTerminatedNCT02585622Phase 1/2
- Complement Inhibition in aHUS Dialysis PatientsTerminatedNCT02464891Phase 2
- Intensive Versus Minimal Surveillance of Patients With Resected Dukes B2-C Colorectal CarcinomaCompletedNCT02409472Not applicable
- Pre-operative Zoledronate in Triple Negative Breast CancerTerminatedNCT02347163Phase 2
- E-learning to Improve the Quality of Drug Prescribing in Hospitalized Elderly PatientsCompletedNCT02339792Not applicable
- Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)TerminatedNCT02338570Phase 4
- GREAT - Good Response With Appropriate TreatmentCompletedNCT02293785
- Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine LeiomyosarcomaCompletedNCT02249702Phase 2
- ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)CompletedNCT02194231Phase 2
- Eculizumab in Primary MPGNCompletedNCT02093533Phase 2
- Pulsed Perfusion for Marginal KidneysCompletedNCT02055950
- L-Cysteine in Peritoneal DialysisCompletedNCT02050139Phase 2
- Mesenchymal Stromal Cells in Kidney Transplant RecipientsTerminatedNCT02012153Phase 1
- An Efficacy Study Of Ortataxel In Recurrent GlioblastomaCompletedNCT01989884Phase 2
- ITACA-S2 (Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach)TerminatedNCT01989858Phase 3
- Sevelamer in Proteinuric CKDCompletedNCT01968759Phase 2
- Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer PainCompletedNCT01946555
- Effects of Caloric Restriction in Obesity and Type 2 DiabetesCompletedNCT01930136Not applicable
- CE-US in Renal TransplantationCompletedNCT01815320Phase 2
- Multicentric Observational Study on Quality of Life in GlaucomaCompletedNCT01742104
- Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian CancerCompletedNCT01735071Phase 2
- CYCLosporinE A in Reperfused Acute Myocardial InfarctionCompletedNCT01650662Phase 3
- Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the StomachCompletedNCT01640782Phase 3
- Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 DiabetesCompletedNCT01393808Phase 2
- Tolvaptan for In-hospital HyponatremiaTerminatedNCT01386372Phase 2
- INOVATYON STUDY -International, Randomized Study in Patients With Ovarian CancerCompletedNCT01379989Phase 3
- Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line Treatment of Advanced or Metastatic Non Small Cell Lung CancerTerminatedNCT01379976Phase 3
- Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal InsufficiencyCompletedNCT01377246Phase 3
- Mesenchymal Stem Cells In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ CancersWithdrawnNCT01275612Phase 1
- Efficacy of Nebulised Beclometasone in Viral Wheezing ProphylaxisCompletedNCT01265342Phase 4
- Telmisartan Versus Losartan in Kidney TransplantationCompletedNCT01224860Phase 2
- Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal InsufficiencyTerminatedNCT01223755Phase 2/3
- Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary HyperparathyroidismCompletedNCT01220050Phase 2
- Nephrolithiasis Prevention by Lemon JuiceCompletedNCT01217372Phase 2
- Preventing Renal Functional Abnormalities With Calorie Restriction in Subjects With Abdominal Obesity and Type 2 Diabetes at Increased Renal and Cardiovascular RiskCompletedNCT01213212Phase 2
- Pragmatic RCT Comparing Aripiprazole, Olanzapine and Haloperidol in the Treatment of SchizophreniaCompletedNCT01052389Phase 4
- Angiotensin-converting-enzyme (ACE) Inhibitors in HemodialysisCompletedNCT00985322Phase 3
- Acetyl-L-Carnitine in Type 2 DiabetesCompletedNCT00984750Phase 3
- Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS)CompletedNCT00981838Phase 3
- Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant ToleranceTerminatedNCT00752479Phase 1/2
- Preventing Microalbuminuria in Type 2 DiabetesCompletedNCT00503152Phase 3
- MMF vs. AZA for Kidney TransplantationCompletedNCT00494741Phase 4
- Preventing ESRD in Overt Nephropathy of Type 2 DiabetesCompletedNCT00494715Phase 3
- Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and SafetyCompletedNCT00491517Phase 2
- Acetylcarnitine and Insulin SensitivityCompletedNCT00393770Phase 2
- Risk and Prevention Study: Evaluation of the Efficacy of n-3 PUFA in Subjects at High Cardiovascular RiskCompletedNCT00317707Phase 3
- Metabolic and Renal Effects of Rosiglitazone in Kidney TransplantCompletedNCT00309309Phase 2
- Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up StudyCompletedNCT00309283Phase 3
- Low Dose Sirolimus or CsA-Based Maintenance Immunosuppression After Induction With Campath-1 in Kidney TransplantationCompletedNCT00309270Phase 2
- Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport SyndromeCompletedNCT00309257Phase 2
- Statins in Proteinuric NephropathiesCompletedNCT00199927Phase 3
- Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND)CompletedNCT00157586Phase 3
- L-Arginine in Pre-EclampsiaCompletedNCT00157521Phase 3
- Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early NephropathyTerminatedNCT00157508Phase 2
- Ezetimibe and Simvastatin in Dyslipidemia of DiabetesCompletedNCT00157482Phase 2
- Enzyme Replacement Therapy in Fabry DiseaseTerminatedNCT00149318
- Genetic Study of Nephrolithiasis in Gouty DiathesisTerminatedNCT00149305
← Mario Negri Institute for Pharmacological Research overview and focus areas